194 related articles for article (PubMed ID: 35125241)
21. CAR NK92 Cells Targeting BCMA Can Effectively Kill Multiple Myeloma Cells Both In Vitro and In Vivo.
Park E; Mun HJ; Seo E; Hwang S; Lee JH; Song S; Sung H; Kim HY; Kwon MJ
Biomedicines; 2024 Jan; 12(1):. PubMed ID: 38275419
[TBL] [Abstract][Full Text] [Related]
22. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
23. CAR-NK cell therapy for hematological malignancies: recent updates from ASH 2022.
Huang R; Wen Q; Zhang X
J Hematol Oncol; 2023 Apr; 16(1):35. PubMed ID: 37029381
[TBL] [Abstract][Full Text] [Related]
24. FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma.
Bigley AB; Spade S; Agha NH; Biswas S; Tang S; Malik MH; Dai L; Masoumi S; Patiño-Escobar B; Hale M; DiPierro G; Martell R; Hann B; Shah N; Wiita AP; Liu X
Blood Adv; 2021 Aug; 5(15):3021-3031. PubMed ID: 34357379
[TBL] [Abstract][Full Text] [Related]
25. Daratumumab augments alloreactive natural killer cell cytotoxicity towards CD38+ multiple myeloma cell lines in a biochemical context mimicking tumour microenvironment conditions.
Mahaweni NM; Bos GMJ; Mitsiades CS; Tilanus MGJ; Wieten L
Cancer Immunol Immunother; 2018 Jun; 67(6):861-872. PubMed ID: 29500635
[TBL] [Abstract][Full Text] [Related]
26. Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment.
Motais B; Charvátová S; Walek Z; Hrdinka M; Smolarczyk R; Cichoń T; Czapla J; Giebel S; Šimíček M; Jelínek T; Ševčíková T; Sobotka J; Kořístek Z; Hájek R; Bagó JR
Cells; 2021 Apr; 10(5):. PubMed ID: 33919155
[TBL] [Abstract][Full Text] [Related]
27. Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.
Swift BE; Williams BA; Kosaka Y; Wang XH; Medin JA; Viswanathan S; Martinez-Lopez J; Keating A
Haematologica; 2012 Jul; 97(7):1020-8. PubMed ID: 22271890
[TBL] [Abstract][Full Text] [Related]
28. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
29. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
[TBL] [Abstract][Full Text] [Related]
30. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.
Jiang H; Zhang W; Shang P; Zhang H; Fu W; Ye F; Zeng T; Huang H; Zhang X; Sun W; Man-Yuen Sze D; Yi Q; Hou J
Mol Oncol; 2014 Mar; 8(2):297-310. PubMed ID: 24388357
[TBL] [Abstract][Full Text] [Related]
31. Anti-myeloma activity of endogenous and adoptively transferred activated natural killer cells in experimental multiple myeloma model.
Alici E; Konstantinidis KV; Sutlu T; Aints A; Gahrton G; Ljunggren HG; Dilber MS
Exp Hematol; 2007 Dec; 35(12):1839-46. PubMed ID: 18036444
[TBL] [Abstract][Full Text] [Related]
32. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
33. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
34. Adoptive Immunotherapy and High-Risk Myeloma.
Duane C; O'Dwyer M; Glavey S
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174099
[TBL] [Abstract][Full Text] [Related]
35. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
36. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
37. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy.
Zhao Y; Zhou X
Immunotherapy; 2020 Jun; 12(9):653-664. PubMed ID: 32436428
[TBL] [Abstract][Full Text] [Related]
38. Adaptive Natural Killer Cells Facilitate Effector Functions of Daratumumab in Multiple Myeloma.
Cho H; Kim KH; Lee H; Kim CG; Chung H; Choi YS; Park SH; Cheong JW; Min YH; Shin EC; Kim JS
Clin Cancer Res; 2021 May; 27(10):2947-2958. PubMed ID: 33602683
[TBL] [Abstract][Full Text] [Related]
39. Cell-based immunotherapy approaches for multiple myeloma.
Kriegsmann K; Kriegsmann M; Cremer M; Schmitt M; Dreger P; Goldschmidt H; Müller-Tidow C; Hundemer M
Br J Cancer; 2019 Jan; 120(1):38-44. PubMed ID: 30518815
[TBL] [Abstract][Full Text] [Related]
40. BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.
Wang Y; Li H; Xu W; Pan M; Qiao C; Cai J; Xu J; Wang M; Zhang J
J Immunother; 2020; 43(6):175-188. PubMed ID: 32349046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
